Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
09 03 2020
09 03 2020
Historique:
received:
29
06
2019
accepted:
03
01
2020
revised:
11
12
2019
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
21
11
2020
Statut:
epublish
Résumé
The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m
Identifiants
pubmed: 32152297
doi: 10.1038/s41408-020-0300-y
pii: 10.1038/s41408-020-0300-y
pmc: PMC7062899
doi:
Substances chimiques
Oligopeptides
0
carfilzomib
72X6E3J5AR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
Blood. 2016 Sep 1;128(9):1174-80
pubmed: 27439911
Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897
pubmed: 29134824
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
J Clin Oncol. 2018 Mar 10;36(8):728-734
pubmed: 29341834
Leukemia. 2017 Jun;31(6):1368-1374
pubmed: 28025582
J Support Oncol. 2003 Nov-Dec;1(4 Suppl 2):18-24
pubmed: 15346996
Blood. 2017 Oct 19;130(16):1845-1856
pubmed: 28716860
Leukemia. 2019 Dec;33(12):2934-2946
pubmed: 31092895
Haematologica. 2020 Jan 31;105(2):468-477
pubmed: 31221782
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Blood Cancer J. 2017 Apr 21;7(4):e554
pubmed: 28430175
Lancet Oncol. 2018 Jul;19(7):953-964
pubmed: 29866475
Med Clin North Am. 2005 May;89(3):649-87
pubmed: 15755472
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Br J Haematol. 2017 May;177(3):404-413
pubmed: 28211560
J Clin Oncol. 2019 May 10;37(14):1228-1263
pubmed: 30932732
Br J Haematol. 2016 Jan;172(1):89-96
pubmed: 26567759
Blood. 2012 Oct 4;120(14):2817-25
pubmed: 22833546
Cancer Med. 2017 Jul;6(7):1523-1530
pubmed: 28612485
Clin Interv Aging. 2016 Apr 15;11:423-35
pubmed: 27143866
Mayo Clin Proc. 2017 Apr;92(4):578-598
pubmed: 28291589
Mayo Clin Proc. 2004 Jul;79(7):867-74
pubmed: 15244382
Crit Rev Oncol Hematol. 2018 Jan;121:74-89
pubmed: 29279102
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Lancet Oncol. 2017 Oct;18(10):1327-1337
pubmed: 28843768
Leukemia. 2016 May;30(5):1005-17
pubmed: 26710887
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Oncologist. 2018 Jun;23(6):734-739
pubmed: 29438096
Haematologica. 2018 Dec;103(12):2079-2087
pubmed: 30237264
Blood Cancer J. 2017 Feb 17;7(2):e528
pubmed: 28211889
J Clin Oncol. 2014 Feb 20;32(6):587-600
pubmed: 24419113
Leuk Lymphoma. 2017 Oct;58(10):2501-2504
pubmed: 28306371
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Leukemia. 2017 Jan;31(1):115-122
pubmed: 27491641
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Leuk Lymphoma. 2007 Feb;48(2):337-41
pubmed: 17325894
Cancer. 2008 Aug 15;113(4):765-71
pubmed: 18543319
J Natl Compr Canc Netw. 2017 Feb;15(2):230-269
pubmed: 28188192
Blood. 2018 Jan 18;131(3):301-310
pubmed: 29150421
J Clin Oncol. 2001 Feb 15;19(4):1147-51
pubmed: 11181680
Haematologica. 2018 Dec;103(12):2088-2096
pubmed: 30237262
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Cancer Treat Rev. 2015 Dec;41(10):827-35
pubmed: 26296679